DK0996468T3 - Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika - Google Patents

Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika

Info

Publication number
DK0996468T3
DK0996468T3 DK98946571T DK98946571T DK0996468T3 DK 0996468 T3 DK0996468 T3 DK 0996468T3 DK 98946571 T DK98946571 T DK 98946571T DK 98946571 T DK98946571 T DK 98946571T DK 0996468 T3 DK0996468 T3 DK 0996468T3
Authority
DK
Denmark
Prior art keywords
galactose
pain
agents
analgesics
conjugates
Prior art date
Application number
DK98946571T
Other languages
English (en)
Inventor
John Andrew Chaddock
Michael John Duggan
Original Assignee
Health Prot Agency
Speywood Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency, Speywood Lab Ltd filed Critical Health Prot Agency
Application granted granted Critical
Publication of DK0996468T3 publication Critical patent/DK0996468T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK98946571T 1997-10-08 1998-10-07 Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika DK0996468T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721189.0A GB9721189D0 (en) 1997-10-08 1997-10-08 Analgesic conjugates
PCT/GB1998/003001 WO1999017806A1 (en) 1997-10-08 1998-10-07 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics

Publications (1)

Publication Number Publication Date
DK0996468T3 true DK0996468T3 (da) 2003-09-15

Family

ID=10820129

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98946571T DK0996468T3 (da) 1997-10-08 1998-10-07 Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika

Country Status (13)

Country Link
US (2) US7052702B1 (da)
EP (1) EP0996468B1 (da)
JP (1) JP4629225B2 (da)
AT (1) ATE240747T1 (da)
AU (1) AU741456B2 (da)
CA (1) CA2306350C (da)
DE (1) DE69814858T2 (da)
DK (1) DK0996468T3 (da)
ES (1) ES2198750T3 (da)
GB (1) GB9721189D0 (da)
PT (1) PT996468E (da)
WO (1) WO1999017806A1 (da)
ZA (1) ZA989138B (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
GB9907429D0 (en) * 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
EP2267010B1 (en) 1999-08-25 2014-05-07 Allergan, Inc. Activatable recombinant neurotoxins
US20090018081A1 (en) * 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
DK1234043T3 (da) * 1999-12-02 2004-07-19 Health Prot Agency Konstruktion for afgivelse af terapeutiske midler til neuroceller
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
AU4904101A (en) * 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
EP1365800B1 (en) * 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
GB0108332D0 (en) * 2001-04-03 2001-05-23 Univ Durham Lectin directed prodrug delivery system
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
AU2005279741B2 (en) * 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
JP2008532549A (ja) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP2505592A1 (en) 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
BRPI0817775A2 (pt) * 2007-10-23 2015-03-24 Allergan Inc Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
JP6336970B2 (ja) 2012-05-30 2018-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
RU2673910C2 (ru) 2012-11-21 2018-12-03 Ипсен Байоинновейшн Лимитед Способ производства протеолитически процессированного полипептида
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
DK3242884T3 (da) 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
DK3274364T3 (da) 2015-03-26 2021-10-18 Harvard College Modificeret botulinumneurotoksin
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
DK3529616T3 (da) 2016-10-20 2023-12-11 Harvard College In vitro- og cellebaserede assays til måling af aktiviteten af botulinum-neurotoksiner
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
EP4313120A1 (en) 2021-03-30 2024-02-07 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
JPH05502880A (ja) 1989-12-22 1993-05-20 セラジェン・インコーポレーテッド トランスロケーション領域および細胞結合領域を有するハイブリッド分子
AU1582692A (en) 1991-03-08 1992-10-06 Protein Design Labs, Inc. Recombinant double chain immunotoxins
WO1993004191A1 (en) 1991-08-15 1993-03-04 Neorx Corporation Noncytolytic toxin conjugates
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
DE4242902A1 (de) 1992-12-18 1994-06-23 Madaus Ag Verfahren zur Herstellung von Lektinkonzentraten aus Mistelextrakten und daraus hergestellte standardisierte Präparate zur Erhöhung der natürlichen Immunresistenz und für die Verwendung in der Tumor-Therapie
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
WO1994028923A1 (en) * 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
ES2319860T3 (es) 1993-12-28 2009-05-14 Allergan, Inc. Uso de toxina botulinica de tipo b para la fabricacion de un medicamento para reducir el dolor asociado a un trastorno muscular.
JP3497554B2 (ja) 1994-03-25 2004-02-16 日本臓器製薬株式会社 新規プリン誘導体及びその薬学的に許容される塩
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP0760681B1 (en) * 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
BR9509903A (pt) 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
US5721207A (en) * 1995-04-18 1998-02-24 Innapharma, Inc. Method for treatment of pain
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
WO1997013410A1 (en) 1995-10-13 1997-04-17 Boston Medical Center Corporation Hybrid molecules containing amidated polypeptide binding ligands
CA2238262A1 (en) 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Therapeutic and diagnostic agents for the treatment of microbial infections
US5760149A (en) 1996-08-23 1998-06-02 Elf Atochem North America, Inc. Poly(monoperoxycarbonates)
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
AU4245097A (en) 1996-08-28 1998-03-19 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for (clostridium botulinum) neurotoxin
DE19735105A1 (de) 1997-08-13 1999-03-04 Univ Albert Ludwigs Freiburg Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
CZ294376B6 (cs) 1998-05-13 2004-12-15 Biotecon Gesellschaft Für Biotechnologische Entwic Hybridní protein a léčivo pro inhibici degranulace žírných buněk
DK1346731T3 (da) 1998-07-22 2007-04-10 Osprey Pharmaceuticals Ltd Konjugater til behandling af inflammatoriske forstyrrelser og tilsvarende vævsskade
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9824282D0 (en) 1998-11-05 1998-12-30 Microbiological Research Agenc Delivery of superoxide dismutase to neuronal cells
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells

Also Published As

Publication number Publication date
GB9721189D0 (en) 1997-12-03
CA2306350A1 (en) 1999-04-15
EP0996468B1 (en) 2003-05-21
DE69814858D1 (de) 2003-06-26
ATE240747T1 (de) 2003-06-15
AU741456B2 (en) 2001-11-29
CA2306350C (en) 2008-09-02
DE69814858T2 (de) 2004-03-11
AU9357498A (en) 1999-04-27
PT996468E (pt) 2003-09-30
US20060121056A1 (en) 2006-06-08
US7052702B1 (en) 2006-05-30
ES2198750T3 (es) 2004-02-01
EP0996468A1 (en) 2000-05-03
ZA989138B (en) 1999-05-27
JP4629225B2 (ja) 2011-02-09
WO1999017806A1 (en) 1999-04-15
US7452543B2 (en) 2008-11-18
JP2001518522A (ja) 2001-10-16

Similar Documents

Publication Publication Date Title
DK0996468T3 (da) Konjugater af galactose-bindende lectiner og clostridiale neurotoksiner som analgesika
WO2001077951A8 (en) System and methods for group retirement plan administration
DE69830743D1 (de) Protease-varianten und zusammensetzungen
CO5170431A1 (es) Preparacion farmaceutica que contiene una de las neurotoxinas botulinicas de clostridium botulinum de los tipos a,b,c,d,e,f, o g, o una mezcla de dos o mas de estas neuroxinas
MXPA03000576A (es) Motivo a base de leucina y neurotoxinas clostridial.
DK0880568T3 (da) Elektrochromt system
ES2139369T5 (es) Disposicion de bisagra con efecto resorte, por ejemplo para cierres de plastico inyectado de una sola pieza.
PT1311504E (pt) Tetrazolil-fenil-acetamidas activadoras da glucoquinase
ATE328110T1 (de) Chromogenes medium zum nachweis von staphylococcus aureus
EP0945750A3 (en) Polarizing beam splitter/combiner
FI946186A0 (fi) Alkalofiilinen Bacillus sp. AC13 ja siitä saatava proteaasi, ksylanaasi, sellulaasi
BR9608647A (pt) Amilase dna e composição de detergente
ATE194645T1 (de) Naphthalinboronsäuren
NO974564L (no) Karbohydratmodifiserte cytostatika
AU2002226395A1 (en) Optical transmission system with raman amplifiers comprising a supervisory system
DK1234043T3 (da) Konstruktion for afgivelse af terapeutiske midler til neuroceller
AU2003295769A1 (en) Treatment of mammalian reaction to ige interactions
BR9911619A (pt) Pestivìrus atenuados
HK1058070A1 (en) Optical isolator with low insertion loss and minimized polarization mode dispersion
NO980923D0 (no) Optisk aktivt fenylpyrimidin-derivat som analgetisk middel
ATE429657T1 (de) Optische faserverbindung mit niedriger polarisationsmodendispersion (pmd) und herstellungsverfahren dafür
IT1265694B1 (it) Preparazione enzimatica stabile comprendente cellulasi e proteasi per ottenere effetti alla moda su tessuti misti
NO904876L (no) Optisk forsterker med aktiv fiber og bredt pumpingsbaand, og beslektet optisk fiber.
CO5280132A1 (es) Cojinete de soporte lateral
DK177791D0 (da) Tensidfrie, faste enzympraeparater omfattende protease som virksomt enzym